- Supported exchanges /
- F /
- 2Q5.F
ENOCHIAN BIOSCI. DL-0001 (2Q5 F) stock market data APIs
Renovaro Inc., a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), and cancer in the United States. The company's product pipeline includes RENB-HV-01 for autologous HIV curative treatment; RENB-HV-12, a therapeutic HIV vaccine; and RENB-HB-01, a gene therapy curative treatment for HBV. It also develops RENB-DC-11, an allogeneic dendritic cell therapeutic vaccine for pancreatic cancer; RENB-DC-12-XX, an allogeneic dendritic cell therapeutic vaccine for other solid tumors; and RENB-HV-21 for treating HIV with allogeneic natural killer (NK) and gamma delta T-cells. It has strategic partnerships with the University of California, Fred Hutchinson Cancer Research Center, and Caring Cross. The company was formerly known as Renovaro Biosciences Inc. and changed its name to Renovaro Inc. in February 2024. Renovaro Inc. is headquartered in Los Angeles, California.
ENOCHIAN BIOSCI. DL-0001 Financial Data Overview
| 0.52 | |
| 0.52 | |
| - | |
| 0.52 | |
| 0.52 | |
| 0.4275-4.84 | |
| 91 012 K | |
| 154 M | |
| 0 | |
| 0.565 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
ENOCHIAN BIOSCI. DL-0001 Fundamental Data is available in our Financial Data APIs
- Net Revenue 0
- EBITDA -24 580 266
- Earnings Per Share -0.72
- Income Statements
- Balance Sheets
- Cash flows
of Fundamental API Data
Get ENOCHIAN BIOSCI. DL-0001 Earnings via APIs
- Latest Release NaN
- EPS/Forecast NaN
Get ENOCHIAN BIOSCI. DL-0001 End-of-day Data via APIs
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
